"After the injection, the eyes don't hurt and swell. Now I feel very good." On March 27, Mr. Tian, who was plagued by macular lesions in his left eye, injected buxizumab, the first imported innovative drug in Zhuhai. This is also the first ophthalmic drug approved for clinical urgent use in medical institutions in Dawan district after the implementation of the "Hong Kong Macao drug and equipment link" in Dawan District, Guangdong, Hong Kong and Macao. Buzurumab is used in the treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). Compared with the existing treatment methods, it can absorb the hydrops in the retina earlier, and has obvious advantages in improving the anatomic structure continuously once every 3 months. It can better meet the treatment needs of prolonging the interval of drug administration, and is beneficial to improving the compliance of patients and greatly improving the quality of life of patients. At present, there are more than 30 million patients with various fundus diseases in China, and more than 3 million new patients with fundus diseases every year, which has become the main blinding eye disease in China, and most of them occur in people over the age of 50. At present, the use of existing therapeutic drugs in China can only make about 50% of patients in treatment get sustained and effective elimination of edema and effusion, and the treatment needs of many patients need to be met urgently. "Smaller molecule buzumab is the first international innovative drug introduced into the field of ocular fundus treatment, which has better fluid control effect than the existing treatment method, which means that the future of the disease in the Gulf area and even the whole Chinese mainland can come to Zhuhai to try this international innovative drug when the existing treatment plan is not satisfactory." Lin Shunchao, Mr. Tian's chief surgeon, said. Mr. Tian, the first injector, told reporters that according to the previous treatment plan, he needs to be injected five to six times a year, while "buxizumab" can reduce the number of injections to three to four times. "Thanks to the 'Hong Kong and Macao drug and equipment link' policy, the introduction of advanced drugs has benefited our patients, received better treatment, and reduced our economic burden to a certain extent." In November 25, 2020, the State Drug Administration issued the "innovation and development plan for drug and medical device supervision in the bay area of Guangdong, Hong Kong and Macao", allowing the designated Hong Kong Medical Institutions in the mainland of the city to use drugs registered in Hongkong and medical devices which are urgently needed by clinical departments, purchased by public hospitals and have advanced clinical applications. (Xinhua News Agency)